Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 855 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blood Coagulation Disorder Clear all
Completed No phase listed Observational

A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients

NCT07805408
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 11:08 AM EDT
Terminated Not applicable Interventional

Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection

NCT01608919
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
blood tests
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 24, 2026, 11:08 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

NCT00630448
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 24, 2026, 11:08 AM EDT
Not listed Phase 1Phase 2 Interventional

CEP-701 (Lestaurtinib) in Myelofibrosis

NCT00668421
View directory record Official record
Conditions
Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera
Interventions
CEP-701 (Lestaurtinib)
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
7
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study to Assess the Changes in Blood Clotting Factors and Blood Vessel Wall Function in Obstructive Sleep Apnea

NCT00936481
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 2 Interventional

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Sym001
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898
View directory record Official record
Conditions
Blood Clot
Interventions
Rivaroxaban, no anticoagulation
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

NCT01439971
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-05280602
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational

Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study

NCT00936845
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Month and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
18
States / cities
Duarte, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 24, 2026, 11:08 AM EDT
Recruiting Phase 1 Interventional

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807
View directory record Official record
Conditions
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions
Emicizumab
Drug
Lead sponsor
Bleeding and Clotting Disorders Institute Peoria, Illinois
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
12
States / cities
Orange, California • Redwood City, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational

Impact of Vasculitis on Employment and Income

NCT02476292
View directory record Official record
Conditions
Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis, Temporal Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa (PAN), Takayasu's Arteritis, Urticarial Vasculitis
Interventions
online questionnaire
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

NCT02830477
View directory record Official record
Conditions
Hemophilia A, Congenital
Interventions
Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Biological
Lead sponsor
Bayer
Industry
Eligibility
Male only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Mobile, Alabama • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 24, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563
View directory record Official record
Conditions
IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis, Henoch-schonlein Purpura Nephritis, IgA Vasculitis
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Factor XIII (FXIII) Concentrate

NCT00640289
View directory record Official record
Conditions
Hemophilia, Factor XIII Deficiency
Interventions
Fibrogammin P
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 24, 2026, 11:08 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Navitoclax, Ruxolitinib, Celecoxib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

NCT01493778
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 24, 2026, 11:08 AM EDT
Completed Phase 4 Interventional Results available

Survey of Inhibitors in Plasma-Product Exposed Toddlers

NCT01064284
View directory record Official record
Conditions
Hemophilia A
Interventions
PLASMA DERIVED Factor VIII, Recombinant FVIII
Drug
Lead sponsor
Fondazione Angelo Bianchi Bonomi
Other
Eligibility
1 Minute to 6 Years · Male only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational

Exploratory Assessment of the Quantra® System in Adult ECMO Patients

NCT05426564
View directory record Official record
Conditions
Blood Loss, Thrombosis, Extracorporeal Circulation; Complications
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 24, 2026, 11:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Factor IX Gene Therapy Study (FIX-GT)

NCT03369444
View directory record Official record
Conditions
Hemophilia B
Interventions
FLT180a
Biological
Lead sponsor
University College, London
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 24, 2026, 11:08 AM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

NCT03818763
View directory record Official record
Conditions
Hemophilia A
Interventions
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 11:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

NCT05987449
View directory record Official record
Conditions
Hemophilia A
Interventions
NXT007
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 59 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
4
States / cities
Sacramento, California • Washington D.C., District of Columbia • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 24, 2026, 11:08 AM EDT
Completed No phase listed Observational

Examining the Experiences of Children With Blood Disorders

NCT04600609
View directory record Official record
Conditions
Blood Disease, Thrombotic Disorder, Venous Thromboembolism, Hemostatic Disorder, Bleeding Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 11:08 AM EDT